clinical MR imaging brain part phase II clinical trial patients presumed intracranial neoplastic disease underwent magnetic resonance MR intravenous injection gadolinium carboxymethyl ododecane neutral nonionic gadolinium chelate osmolality equimolar concentrations superior vitro stability gadopentetate dimeglumine safety profile permitted administration doses mmol/kg times dose gadopentetate dimeglumine Food Drug Administration limited clinical trial safe efficacious agent MR imaging head change patient monitoring slight skin redness injection site administration patients significant changes due administration agent laboratory evaluations results gadopentetate transient rise serum iron bilirubin levels patients Administration doses mmol/kg improved enhancement decrease efficacy high doses 